Market stress hit US health insurers head-on after the Trump administration floated a 2027 Medicare Advantage payment update that upended earnings math across the sector. Investors moved fast. So did executives, actuaries, and strategy teams.
Equity markets elsewhere leaned upbeat, lifted by tech and a fresh S&P 500 record, yet managed care traded in its own ugly lane as tens of $bn in value vanished before lunch.
The trigger sits inside a proposal from the Centers for Medicare and Medicaid Services. CMS outlined an average Medicare Advantage payment lift of 0.09% for 2027.
Wall Street models, and most internal carrier forecasts, sat closer to 4-6%. The gap matters. Once medical inflation, utilisation, wages, and benefit creep enter the picture, executives aren’t reading the number as an increase.
Stocks priced it that way:
- UnitedHealth Group dropped about 18% to roughly $286.68.
- Humana slid more than 19% to near $213.
- CVS Health and Elevance Health together lost over $20 bn in market capitalisation.
Major insurers saw their stocks tumble sharply after the Trump administration proposed holding Medicare payments roughly flat in 2027. The small-than-expected increase comes amid concerns about rising health costs.
UnitedHealth Group released fourth-quarter earnings before Tuesday’s opening bell, with RBC analysts saying the earnings print and 2026 outlook were both “solid.” They chalked up the big slide in the shares to the latest insurance updates from the administration.
During the earnings call, UnitedHealthcare CEO Tim Noel called the CMS proposal “disappointing,” saying if finalized, “it will mean very meaningful benefit reductions.”
The damage stung more because Medicare Advantage has carried growth expectations for years, propped up by generous federal payments and favourable risk scoring. That formula looks shakier now.
For insurers, the issue runs deeper than a bad trading day. The proposed rates arrive with cost pressure already intense.
Senior medical trends keep running hot as deferred care returns, acuity rises, and high-ticket therapies spread. Labour and administrative costs stay elevated, especially in care management and clinical roles.
Oversight around risk adjustment and coding keeps tightening, shrinking room to offset weak headline rates through documentation.
